Concepedia

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

Chris Parker, Daniel Heinrich, Joe M. O’Sullivan, Sophie D. Fosså, Aleš Chodacki, Tomasz Demkow, A.J. Cross, B. Bolstad, J. Garcia‐Vargas, Oliver Sartor

European Journal of Cancer · 2011 · 137 citations · 0 references

Concepts

Radiation MedicineUrologyRadiation TherapyMedicineRadium-223 ChlorideOverall Survival BenefitCastration-resistant Prostate CancerCancer TreatmentProstatic DiseaseOncologyRadiation Oncology